» Authors » M C Benyunes

M C Benyunes

Explore the profile of M C Benyunes including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 22
Citations 112
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Wolff S, Herzig R, Lynch J, Ericson S, Greer J, Stein R, et al.
Bone Marrow Transplant . 2001 Mar; 27(3):261-8. PMID: 11277173
Thrombocytopenia following myelotoxic therapy is a common problem and when severe (<20,000/microl) can lead to severe morbidity and mortality. Thrombopoietin (TPO) is a naturally occurring glycosylated peptide which stimulates the...
2.
Fefer A, Robinson N, Benyunes M, Bensinger W, Press O, Thompson J, et al.
Cancer J Sci Am . 1998 Feb; 3 Suppl 1:S48-53. PMID: 9457394
Purpose: Autologous or allogeneic bone marrow transplantation (BMT) or stem cell transplantation (SCT) for advanced hematologic malignancies is associated with a high relapse rate. It has been postulated that recombinant...
3.
Mogul M, Forte K, Holland H, Turner C, Benyunes M, Yeager A
J Pediatr Hematol Oncol . 1997 Mar; 19(2):142-4. PMID: 9149745
Purpose: This study evaluated the feasibility of performing haploidentical CD34+ selected transplants for children with Down's syndrome (DS) and recurrent leukemia. Patients And Methods: Within a cohort of 15 children,...
4.
Robinson N, Benyunes M, Thompson J, York A, Petersdorf S, Press O, et al.
Bone Marrow Transplant . 1997 Mar; 19(5):435-42. PMID: 9052908
The success of autologous stem cell transplantation (ASCT) for hematologic malignancy is limited largely by a high relapse rate. It is postulated that IL-2 administered after ASCT may eliminate minimal...
5.
Massumoto C, Benyunes M, Sale G, Beauchamp M, York A, Thompson J, et al.
Bone Marrow Transplant . 1996 Mar; 17(3):351-6. PMID: 8704686
The high relapse rate of hematologic malignancy treated with autologous bone marrow transplantation (ABMT) may reflect the absence of a graft-versus-leukemia (GVL) effect usually associated with graft-versus-host disease (GVHD). The...
6.
Robinson N, Sanders J, Benyunes M, Beach K, Lindgren C, Thompson J, et al.
Blood . 1996 Feb; 87(4):1249-54. PMID: 8608212
Allogeneic bone marrow transplantation (BMT) for advanced acute leukemia is associated with a high risk of relapse. It is postulated that interleukin-2 (IL-2) administered after BMT might induce or amplify...
7.
Benyunes M, Higuchi C, York A, Lindgren C, Thompson J, Buckner C, et al.
Bone Marrow Transplant . 1995 Aug; 16(2):283-8. PMID: 7581149
Early relapse remains a major challenge after autologous bone marrow transplant for malignant lymphoma (ML). It is postulated that consolidative immunotherapy with interleukin 2 (IL-2) with or without lymphokine-activated killer...
8.
Benyunes M, Sullivan K, Deeg H, Mori M, Meyer W, Fisher L, et al.
Int J Radiat Oncol Biol Phys . 1995 Jun; 32(3):661-70. PMID: 7790252
Purpose: To determine the risk of, and risk factors for, developing cataracts after bone marrow transplantation. Methods And Materials: Four hundred and ninety-two adults who underwent bone marrow transplantation in...
9.
Thompson J, Bianco J, Benyunes M, Neubauer M, Slattery J, Fefer A
Cancer Res . 1994 Jul; 54(13):3436-41. PMID: 8012963
The dose of interleukin 2 (IL-2) which can be administered to cancer patients is limited largely by a capillary leak syndrome. Pentoxifylline (PTX) is a methylxanthine which reduces IL-2 toxicity...
10.
Neubauer M, Benyunes M, Thompson J, Bensinger W, Lindgren C, Buckner C, et al.
Bone Marrow Transplant . 1994 Mar; 13(3):311-6. PMID: 7911048
Immunotherapy with interleukin-2 (IL-2) early after peripheral blood stem cell transplantation (PBSCT) is being considered as a potential way to eradicate minimal residual disease. The aim of this study was...